Eintrag weiter verarbeiten
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Blood, 112, 2008, 11, S. 4424-4424 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Ferreira, Rosa Branca Vaz, Carlos Pinho Barbosa, Isabel Roncon, Susana Campilho, Fernando Carvalhais, Alzira Martinho, A. Campos, Antonio Ferreira, Rosa Branca Vaz, Carlos Pinho Barbosa, Isabel Roncon, Susana Campilho, Fernando Carvalhais, Alzira Martinho, A. Campos, Antonio |
|---|---|
| author |
Ferreira, Rosa Branca Vaz, Carlos Pinho Barbosa, Isabel Roncon, Susana Campilho, Fernando Carvalhais, Alzira Martinho, A. Campos, Antonio |
| spellingShingle |
Ferreira, Rosa Branca Vaz, Carlos Pinho Barbosa, Isabel Roncon, Susana Campilho, Fernando Carvalhais, Alzira Martinho, A. Campos, Antonio Blood Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center Cell Biology Hematology Immunology Biochemistry |
| author_sort |
ferreira, rosa branca |
| spelling |
Ferreira, Rosa Branca Vaz, Carlos Pinho Barbosa, Isabel Roncon, Susana Campilho, Fernando Carvalhais, Alzira Martinho, A. Campos, Antonio 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v112.11.4424.4424 <jats:title>Abstract</jats:title> <jats:p>Allogeneic stem cell transplantation is an accepted treatment modality for selected malignant diseases. However, the ability to identify suitable related or unrelated donors can be difficult in some patients (pts). Alternative sources of stem cells such as cord blood (UCB) provide a readily available graft mainly for pediatric patients. Between October 1996 and May 2008, 23 consecutive patients (pts), with a median age of 6 years old (range:1 – 11), 13 male and 10 female, underwent UCB transplant for the treatment of acute lymphoblastic leukemia (n= 15), acute myeloid leukemia (n=7) and acute byphenotypic leukemia (n= 1). Conditioning regimen consisted of intravenous busulfan (3.2 mg/kg/day x 4 days), cyclophosphamide (120 mg/Kg) and rabbit antithymocyte globuline (15 mg/Kg) ±melphalan (140 mg/m2) and GVHD prophylaxis consisted of a calcineurin inhibitor and MMF or MTX. All grafts were HLA mismatched. The median infused cell doses were, respectively 3.2× 107/kg (range: 1.2–21) and 1.27×105/kg (range:0.2–4.3) for nucleated cells (NC) and CD34 + cells. Engraftment occurred in 18 pts (75%). Five pts failed engraftment, of wich 4 underwent a second transplant (3 autologous and 1 haploidentical) and 1 died of infection at day +59. Grade II–IV acute GVHD occurred in 12 pt and chronic GVHD in 2 of 14 pt at risk. With a median follow up of 1,5 years (range: 3 months-9.5 years), overall survival (OS) at 3 years is 40% (± 13%) and event free survival (EFS) at 3 years is 32% (± 11%). Non relapse mortality (NRM) was 13.6 % (± 7.3%). UCB transplants represents a valuable alternative to bone marrow or peripheral blood especially for pts requiring urgent transplant or lacking an HLA matched unrelated donor and having the potential advantage of an immune tolerance allowing successful transplantation despite HLA disparity</jats:p> Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center Blood |
| doi_str_mv |
10.1182/blood.v112.11.4424.4424 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjQ0MjQuNDQyNA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjQ0MjQuNDQyNA |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
American Society of Hematology, 2008 |
| imprint_str_mv |
American Society of Hematology, 2008 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
ferreira2008unrelatedcordbloodtransplantsinchildrenwithacuteleukemiaexperienceofasinglecenter |
| publishDateSort |
2008 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_unstemmed |
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_full |
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_fullStr |
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_full_unstemmed |
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_short |
Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_sort |
unrelated cord blood transplants in children with acute leukemia: experience of a single center |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood.v112.11.4424.4424 |
| publishDate |
2008 |
| physical |
4424-4424 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Allogeneic stem cell transplantation is an accepted treatment modality for selected malignant diseases. However, the ability to identify suitable related or unrelated donors can be difficult in some patients (pts). Alternative sources of stem cells such as cord blood (UCB) provide a readily available graft mainly for pediatric patients. Between October 1996 and May 2008, 23 consecutive patients (pts), with a median age of 6 years old (range:1 – 11), 13 male and 10 female, underwent UCB transplant for the treatment of acute lymphoblastic leukemia (n= 15), acute myeloid leukemia (n=7) and acute byphenotypic leukemia (n= 1). Conditioning regimen consisted of intravenous busulfan (3.2 mg/kg/day x 4 days), cyclophosphamide (120 mg/Kg) and rabbit antithymocyte globuline (15 mg/Kg) ±melphalan (140 mg/m2) and GVHD prophylaxis consisted of a calcineurin inhibitor and MMF or MTX. All grafts were HLA mismatched. The median infused cell doses were, respectively 3.2× 107/kg (range: 1.2–21) and 1.27×105/kg (range:0.2–4.3) for nucleated cells (NC) and CD34 + cells. Engraftment occurred in 18 pts (75%). Five pts failed engraftment, of wich 4 underwent a second transplant (3 autologous and 1 haploidentical) and 1 died of infection at day +59. Grade II–IV acute GVHD occurred in 12 pt and chronic GVHD in 2 of 14 pt at risk. With a median follow up of 1,5 years (range: 3 months-9.5 years), overall survival (OS) at 3 years is 40% (± 13%) and event free survival (EFS) at 3 years is 32% (± 11%). Non relapse mortality (NRM) was 13.6 % (± 7.3%). UCB transplants represents a valuable alternative to bone marrow or peripheral blood especially for pts requiring urgent transplant or lacking an HLA matched unrelated donor and having the potential advantage of an immune tolerance allowing successful transplantation despite HLA disparity</jats:p> |
| container_issue |
11 |
| container_start_page |
4424 |
| container_title |
Blood |
| container_volume |
112 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792324825692241928 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:55:50.871Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Unrelated+Cord+Blood+Transplants+in+Children+with+Acute+Leukemia%3A+Experience+of+a+Single+Center&rft.date=2008-11-16&genre=article&issn=1528-0020&volume=112&issue=11&spage=4424&epage=4424&pages=4424-4424&jtitle=Blood&atitle=Unrelated+Cord+Blood+Transplants+in+Children+with+Acute+Leukemia%3A+Experience+of+a+Single+Center&aulast=Campos&aufirst=Antonio&rft_id=info%3Adoi%2F10.1182%2Fblood.v112.11.4424.4424&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792324825692241928 |
| author | Ferreira, Rosa Branca, Vaz, Carlos Pinho, Barbosa, Isabel, Roncon, Susana, Campilho, Fernando, Carvalhais, Alzira, Martinho, A., Campos, Antonio |
| author_facet | Ferreira, Rosa Branca, Vaz, Carlos Pinho, Barbosa, Isabel, Roncon, Susana, Campilho, Fernando, Carvalhais, Alzira, Martinho, A., Campos, Antonio, Ferreira, Rosa Branca, Vaz, Carlos Pinho, Barbosa, Isabel, Roncon, Susana, Campilho, Fernando, Carvalhais, Alzira, Martinho, A., Campos, Antonio |
| author_sort | ferreira, rosa branca |
| container_issue | 11 |
| container_start_page | 4424 |
| container_title | Blood |
| container_volume | 112 |
| description | <jats:title>Abstract</jats:title> <jats:p>Allogeneic stem cell transplantation is an accepted treatment modality for selected malignant diseases. However, the ability to identify suitable related or unrelated donors can be difficult in some patients (pts). Alternative sources of stem cells such as cord blood (UCB) provide a readily available graft mainly for pediatric patients. Between October 1996 and May 2008, 23 consecutive patients (pts), with a median age of 6 years old (range:1 – 11), 13 male and 10 female, underwent UCB transplant for the treatment of acute lymphoblastic leukemia (n= 15), acute myeloid leukemia (n=7) and acute byphenotypic leukemia (n= 1). Conditioning regimen consisted of intravenous busulfan (3.2 mg/kg/day x 4 days), cyclophosphamide (120 mg/Kg) and rabbit antithymocyte globuline (15 mg/Kg) ±melphalan (140 mg/m2) and GVHD prophylaxis consisted of a calcineurin inhibitor and MMF or MTX. All grafts were HLA mismatched. The median infused cell doses were, respectively 3.2× 107/kg (range: 1.2–21) and 1.27×105/kg (range:0.2–4.3) for nucleated cells (NC) and CD34 + cells. Engraftment occurred in 18 pts (75%). Five pts failed engraftment, of wich 4 underwent a second transplant (3 autologous and 1 haploidentical) and 1 died of infection at day +59. Grade II–IV acute GVHD occurred in 12 pt and chronic GVHD in 2 of 14 pt at risk. With a median follow up of 1,5 years (range: 3 months-9.5 years), overall survival (OS) at 3 years is 40% (± 13%) and event free survival (EFS) at 3 years is 32% (± 11%). Non relapse mortality (NRM) was 13.6 % (± 7.3%). UCB transplants represents a valuable alternative to bone marrow or peripheral blood especially for pts requiring urgent transplant or lacking an HLA matched unrelated donor and having the potential advantage of an immune tolerance allowing successful transplantation despite HLA disparity</jats:p> |
| doi_str_mv | 10.1182/blood.v112.11.4424.4424 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjQ0MjQuNDQyNA |
| imprint | American Society of Hematology, 2008 |
| imprint_str_mv | American Society of Hematology, 2008 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T11:55:50.871Z |
| match_str | ferreira2008unrelatedcordbloodtransplantsinchildrenwithacuteleukemiaexperienceofasinglecenter |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 4424-4424 |
| publishDate | 2008 |
| publishDateSort | 2008 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Ferreira, Rosa Branca Vaz, Carlos Pinho Barbosa, Isabel Roncon, Susana Campilho, Fernando Carvalhais, Alzira Martinho, A. Campos, Antonio 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v112.11.4424.4424 <jats:title>Abstract</jats:title> <jats:p>Allogeneic stem cell transplantation is an accepted treatment modality for selected malignant diseases. However, the ability to identify suitable related or unrelated donors can be difficult in some patients (pts). Alternative sources of stem cells such as cord blood (UCB) provide a readily available graft mainly for pediatric patients. Between October 1996 and May 2008, 23 consecutive patients (pts), with a median age of 6 years old (range:1 – 11), 13 male and 10 female, underwent UCB transplant for the treatment of acute lymphoblastic leukemia (n= 15), acute myeloid leukemia (n=7) and acute byphenotypic leukemia (n= 1). Conditioning regimen consisted of intravenous busulfan (3.2 mg/kg/day x 4 days), cyclophosphamide (120 mg/Kg) and rabbit antithymocyte globuline (15 mg/Kg) ±melphalan (140 mg/m2) and GVHD prophylaxis consisted of a calcineurin inhibitor and MMF or MTX. All grafts were HLA mismatched. The median infused cell doses were, respectively 3.2× 107/kg (range: 1.2–21) and 1.27×105/kg (range:0.2–4.3) for nucleated cells (NC) and CD34 + cells. Engraftment occurred in 18 pts (75%). Five pts failed engraftment, of wich 4 underwent a second transplant (3 autologous and 1 haploidentical) and 1 died of infection at day +59. Grade II–IV acute GVHD occurred in 12 pt and chronic GVHD in 2 of 14 pt at risk. With a median follow up of 1,5 years (range: 3 months-9.5 years), overall survival (OS) at 3 years is 40% (± 13%) and event free survival (EFS) at 3 years is 32% (± 11%). Non relapse mortality (NRM) was 13.6 % (± 7.3%). UCB transplants represents a valuable alternative to bone marrow or peripheral blood especially for pts requiring urgent transplant or lacking an HLA matched unrelated donor and having the potential advantage of an immune tolerance allowing successful transplantation despite HLA disparity</jats:p> Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center Blood |
| spellingShingle | Ferreira, Rosa Branca, Vaz, Carlos Pinho, Barbosa, Isabel, Roncon, Susana, Campilho, Fernando, Carvalhais, Alzira, Martinho, A., Campos, Antonio, Blood, Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_full | Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_fullStr | Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_full_unstemmed | Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_short | Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| title_sort | unrelated cord blood transplants in children with acute leukemia: experience of a single center |
| title_unstemmed | Unrelated Cord Blood Transplants in Children with Acute Leukemia: Experience of a Single Center |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood.v112.11.4424.4424 |